Unlock AI-driven, actionable R&D insights for your next breakthrough.

Creatine Phosphate Manufacturer: Comprehensive Analysis Of Production Technologies, Quality Standards, And Industrial Applications

NOV 17, 202655 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Creatine phosphate (phosphocreatine), a critical high-energy phosphate compound in cellular metabolism, serves as a rapid ATP regeneration reservoir in muscle and neural tissues. As a pharmaceutical intermediate and therapeutic agent for myocardial protection and energy supplementation, creatine phosphate manufacturing demands rigorous process control, high-purity synthesis routes, and compliance with stringent regulatory standards. This article provides an in-depth examination of industrial-scale creatine phosphate production methodologies, quality assurance frameworks, and emerging innovations tailored for R&D professionals seeking to optimize manufacturing efficiency and product performance.
Want to know more material grades? Try Patsnap Eureka Material.

Chemical Synthesis Routes For Creatine Phosphate Manufacturing

Creatine phosphate (N-phosphorylcreatine, CAS 67-07-2) is synthesized industrially through multiple chemical pathways, each presenting distinct advantages in yield, purity, and scalability. The classical phosphorylation approach employs phosphorus oxychloride (POCl₃) as the phosphorylating agent, reacting with creatine in strongly alkaline media (pH >12) at controlled temperatures (0–10°C) 3. This method, pioneered by Zeile and Fawaz in 1938 and refined by Ennor and Stocken in 1948, achieves creatine phosphorylation via direct P–N bond formation but suffers from moderate yields (40–60%) and requires precise pH maintenance to prevent hydrolytic degradation 9. The reaction generates sodium triphosphate slurries that complicate large-scale stirring and cooling, necessitating specialized reactor designs with enhanced heat transfer capabilities 3.

An alternative enzymatic route utilizes creatine phosphokinase (CPK) in the presence of adenosine triphosphate (ATP) and 3-phosphoglyceric acid as phosphate donors 3. This biocatalytic process operates under mild alkaline conditions (pH 8.5–9.5) at 25–37°C, followed by brief thermal denaturation (70–100°C, 5–10 min) to inactivate enzymes and facilitate product isolation 3. While enzymatic synthesis offers high specificity and avoids toxic reagents, the requirement for expensive purified CPK and ATP limits its industrial adoption to analytical-scale applications 3. Recent patents describe hybrid approaches combining chemical phosphorylation with enzymatic refinement to balance cost-effectiveness and product purity 5.

A novel barium-free synthesis pathway addresses heavy metal contamination concerns inherent in traditional methods 45. This process involves reacting creatinine phosphoryl chloride with carboxylic acid salts (e.g., sodium isooctanoate) in aprotic solvents (ethyl acetate) at 0–5°C to form lipophilic creatinine phosphate carboxylic anhydrides 4. Subsequent hydrolysis with 20% sodium hydroxide solution at controlled temperatures yields creatinine phosphate sodium, which undergoes ring-opening hydrolysis at 80°C (pH 8–9) to produce creatine phosphate disodium with purities exceeding 99.5% (HPLC) 4. This method eliminates barium sulfate precipitation steps, reduces heavy metal residues to <5 ppm, and shortens production cycles by 30–40% compared to conventional routes 4.

The chlorophosphoric acid route represents another advancement, wherein phosphorus oxychloride is pre-hydrolyzed to chlorophosphoric acid (H₂PO₃Cl) before reacting with S-methylisothiourea sulfate in dipolar aprotic solvents (DMF, DMSO) 5. The resulting phosphorylated intermediate reacts with sarcosine to form creatine phosphate, which is neutralized with sodium hydroxide or sodium methoxide to pH 8–9, followed by ethanol-induced crystallization 5. This approach reduces POCl₃ consumption by 60%, minimizes gaseous byproducts (HCl, Cl₂), and achieves yields of 75–85% with simplified downstream processing 5.

Precursor Materials And Quality Specifications For Creatine Phosphate Production

High-purity creatine monohydrate (≥99.5% assay, <0.01% creatinine) serves as the primary precursor for creatine phosphate synthesis 7. Industrial-grade creatine is typically produced via the Sarcosine-Cyanamide condensation route, where sodium or potassium sarcosinate reacts with cyanamide at 80–120°C under alkaline conditions (pH 9.5–10.5) 7. The use of carbonic acid for pH adjustment instead of mineral acids (HCl, H₂SO₄) prevents chloride or sulfate contamination, reduces corrosion of reactor vessels, and lowers organic carbon load in wastewater by 40–50% 7. Creatine monohydrate crystallizes upon cooling and ethanol addition, yielding products with residual moisture <0.5% and heavy metals <10 ppm 7.

Phosphorylating agents must meet stringent purity criteria: phosphorus oxychloride (≥99.0%, <0.05% POCl₂), 3-phosphoglyceric acid (≥98%, enzymatic grade), and ATP (disodium salt, ≥95%) 3. For enzymatic routes, creatine phosphokinase activity should exceed 200 U/mg protein, with minimal contamination by ATPases or phosphatases that degrade ATP or creatine phosphate 3. Solvents such as ethyl acetate (≥99.5%, <0.01% water) and dimethylformamide (anhydrous, ≥99.8%) are critical for anhydride formation and phosphorylation reactions, as trace moisture hydrolyzes reactive intermediates and reduces yields by 15–25% 45.

Alkaline reagents include sodium hydroxide (≥98%, low-carbonate grade) and sodium methoxide (25–30% in methanol), with carbonate content <0.5% to prevent CO₂ interference during pH-sensitive cyclization steps 45. Carboxylic acid salts (sodium acetate, sodium isooctanoate) must be anhydrous (≥99%) to avoid premature hydrolysis of mixed anhydrides 4. Quality control protocols mandate ICP-MS analysis for heavy metals (Ba, Pb, As <1 ppm each), ion chromatography for chloride and sulfate (<50 ppm), and Karl Fischer titration for residual water (<0.3%) in final creatine phosphate products 45.

Industrial Manufacturing Processes And Scale-Up Considerations

Large-scale creatine phosphate production employs batch or semi-continuous reactors with capacities ranging from 500 L to 5,000 L, constructed from glass-lined steel or Hastelloy to resist corrosive alkaline and chlorinated environments 34. Temperature control is critical: phosphorylation reactions are maintained at 0–10°C using jacketed vessels with recirculating ethylene glycol-water coolant, while enzymatic syntheses operate at 25–37°C with ±0.5°C precision via PID-controlled heating mantles 3. Agitation systems utilize anchor or helical ribbon impellers (50–150 rpm) to ensure homogeneous mixing of viscous slurries without excessive shear that denatures enzymes or fragments precipitates 34.

The barium-free synthesis process integrates inline filtration and solvent recovery modules 4. After anhydride formation in ethyl acetate, the reaction mixture is filtered through 10 µm cartridge filters to remove sodium chloride byproducts, and the filtrate is concentrated under vacuum (50–100 mbar, 40°C) to recover 85–90% of ethyl acetate for recycling 4. Hydrolysis and ring-opening steps are conducted in glass-lined reactors equipped with automated pH probes and NaOH dosing pumps to maintain pH 8.0–9.0 (±0.1 units), preventing over-alkalization that degrades creatine phosphate into inorganic phosphate and creatinine 4. Crystallization is induced by slow ethanol addition (1–2 L/min per 100 L batch) at 15–20°C, with seeding (0.1–0.5% w/w creatine phosphate crystals) to control particle size distribution (D₅₀ = 50–150 µm) and improve filtration rates 45.

Enzymatic routes require bioreactor systems with dissolved oxygen monitoring and ATP regeneration cycles 3. Creatine (0.2–0.5 M) and 3-phosphoglyceric acid (0.3–0.6 M) are incubated with muscle extract (10–20 mg protein/mL) and catalytic ATP (1–5 mM) in phosphate-buffered saline (pH 8.5) at 30°C for 2–4 hours 3. Oxygen sparging (0.1–0.5 vvm) maintains aerobic conditions for enzyme stability, while inline HPLC monitors creatine phosphate accumulation 3. Thermal inactivation at 85°C for 10 minutes precipitates denatured proteins, which are removed by centrifugation (8,000 × g, 15 min) before product purification via ion-exchange chromatography 3.

Downstream purification employs strongly anionic resins (Amberlite IRA-400, Dowex 1×8) to selectively bind creatine phosphate anions from crude reaction mixtures 18. The resin is eluted with 0.5–1.0 M sodium chloride gradients, and eluates are desalted by nanofiltration (MWCO 200–500 Da) or diafiltration to reduce NaCl to <0.1% 18. Final creatine phosphate disodium is precipitated by ethanol addition (3:1 v/v ethanol:water), filtered, washed with cold ethanol, and vacuum-dried at 40–50°C to residual moisture <1.0% 418. Spray-drying or lyophilization may be employed for pharmaceutical-grade products requiring sterile, pyrogen-free specifications (<0.5 EU/mg) 4.

Analytical Methods And Quality Control Standards For Creatine Phosphate

Creatine phosphate purity is quantified by high-performance liquid chromatography (HPLC) using reversed-phase columns (C₁₈, 250 × 4.6 mm, 5 µm) with UV detection at 210 nm 45. Mobile phases consist of 10 mM potassium phosphate buffer (pH 6.5) with 2–5% acetonitrile, achieving baseline separation of creatine phosphate (retention time ~8 min) from creatine (~5 min), creatinine (~12 min), and inorganic phosphate (~3 min) 4. Quantification employs external calibration curves (0.05–2.0 mg/mL, R² >0.999), with limits of detection (LOD) <5 µg/mL and limits of quantification (LOQ) <15 µg/mL 45. Assay results for pharmaceutical-grade creatine phosphate disodium typically range from 98.5% to 101.5% on an anhydrous, sodium-free basis 4.

Nuclear magnetic resonance (NMR) spectroscopy (³¹P and ¹H NMR) confirms structural integrity and detects phosphorylated impurities 45. ³¹P NMR spectra in D₂O exhibit a characteristic singlet at δ 2.5–3.0 ppm for the N–P bond of creatine phosphate, with absence of signals at δ 0–1 ppm (inorganic phosphate) or δ 18–20 ppm (pyrophosphate) indicating high purity 5. ¹H NMR verifies the creatine moiety via methyl singlet (δ 3.0 ppm) and methylene doublet (δ 3.8 ppm), with integration ratios matching theoretical values (3:2) 5.

Heavy metal analysis by inductively coupled plasma mass spectrometry (ICP-MS) ensures compliance with ICH Q3D guidelines: barium <10 ppm, lead <5 ppm, arsenic <2 ppm, and mercury <1 ppm 45. Residual solvents (ethyl acetate, ethanol, DMF) are quantified by gas chromatography with flame ionization detection (GC-FID) using headspace injection, with acceptance limits of <5,000 ppm (ethanol), <500 ppm (ethyl acetate), and <88 ppm (DMF) per ICH Q3C 45. Chloride and sulfate ions are measured by ion chromatography (IC) with conductivity detection, maintaining levels <200 ppm and <100 ppm, respectively, to prevent corrosion in injectable formulations 45.

Stability testing under ICH guidelines (25°C/60% RH, 40°C/75% RH) monitors creatine phosphate degradation to creatine and inorganic phosphate over 6–24 months 4. Degradation kinetics follow pseudo-first-order models, with degradation rate constants (k) of 0.002–0.005 month⁻¹ at 25°C and 0.010–0.020 month⁻¹ at 40°C 4. Packaging in moisture-barrier aluminum foil laminates (<0.5 g H₂O/m²/24 h) extends shelf life to >36 months at ambient conditions 4.

Formulation Development And Pharmaceutical Applications Of Creatine Phosphate

Creatine phosphate is formulated as lyophilized injectable powders for reconstitution, typically containing 1.0–2.0 g creatine phosphate disodium per vial with mannitol (50–100 mg) as a bulking agent and citric acid/sodium citrate (10–20 mg) as pH buffers (pH 7.0–8.0) 6. Lyophilization cycles involve freezing at −45°C, primary drying at −20°C (50 mTorr, 24–36 h), and secondary drying at 25°C (10 mTorr, 12–18 h) to achieve residual moisture <1.0% and cake appearance scores >4/5 6. Reconstituted solutions (50–100 mg/mL in sterile water) exhibit osmolality of 280–320 mOsm/kg and pH 7.2–7.8, suitable for intravenous or intramuscular administration 6.

Oral formulations include tablets and capsules combining creatine phosphate with dicalcium phosphate (stabilizer), polyvinylpyrrolidone (binder), and magnesium stearate (lubricant) 28. Tablets are compressed at 10–15 kN using rotary presses, yielding hardness of 60–100 N and friability <0.5% 8. Shellac or hydroxypropyl methylcellulose (HPMC) coatings (5–10 mg/cm²) mask taste, prevent moisture uptake (<2% weight gain at 75% RH), and extend shelf life to >24 months 28. Controlled-release formulations employ ethylcellulose or Eudragit matrices to achieve zero-order release kinetics (50–70% released over 6–8 hours) in simulated gastric and intestinal fluids 2.

Liquid nutritional supplements stabilize creatine phosphate using diol-polyol mixtures (propylene glycol 10–20%, glycerol 5–15%) that hydrogen-bond with phosphate groups, reducing hydrolysis rates by 60–75% over 12 months at 25°C 14. Formulations include creatine phosphate (3–5 g per 30 mL serving), natural flavors (5 mL), potassium sorbate (200 µg, preservative), and water-glycerol co-solvents adjusted to pH 6.5–7.5 with citric acid 814. Aseptic filling into HDPE bottles with induction-sealed caps maintains microbial counts <10 CFU/mL and

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
ALZCHEM AGSports nutrition and dietary supplements requiring stable creatine delivery systems for muscle performance enhancement and energy supplementation.Creatine Protein MatrixDeveloped creatine-protein matrix formulation with enhanced stability and bioavailability through optimized manufacturing process combining creatine monohydrate with protein carriers.
ZHONGSHAN BELLING BIO TECHNOLOGY CO. LTD.Pharmaceutical-grade injectable formulations for myocardial protection, cardiac surgery pre-treatment, and therapeutic energy supplementation in clinical settings.High-Purity Creatine Phosphate SodiumAchieved >99.5% purity creatine phosphate disodium via barium-free synthesis route, eliminating heavy metal residues (<5 ppm) and reducing production cycle by 30-40% compared to conventional methods.
NANJING CUCCESS PHARMACEUTICAL CO. LTD.Large-scale pharmaceutical manufacturing requiring environmentally compliant processes for creatine phosphate production with reduced waste generation and improved safety profiles.Creatine Phosphate Sodium (Barium-Free Process)Implemented chlorophosphoric acid route reducing POCl₃ consumption by 60%, achieving 75-85% yields with simplified downstream processing and minimal gaseous byproducts (HCl, Cl₂).
BASF AKTIENGESELLSCHAFTIndustrial-scale creatine precursor production for pharmaceutical and nutritional supplement applications requiring high-purity (≥99.5%) creatine with minimal environmental impact.Creatine Monohydrate (Carbonic Acid Process)Developed creatine synthesis using carbonic acid for pH adjustment instead of mineral acids, reducing chloride/sulfate contamination and lowering organic carbon wastewater load by 40-50%.
BOEHRINGER MANNHEIM GMBHAnalytical-scale and specialized pharmaceutical applications requiring high-specificity creatine phosphate synthesis without toxic chemical reagents for research and therapeutic development.Enzymatic Creatine Phosphate Production SystemEstablished enzymatic phosphorylation process using muscle extract and creatine phosphokinase with 3-phosphoglyceric acid, enabling creatine phosphate synthesis under mild alkaline conditions (pH 8.5-9.5) at 25-37°C.
Reference
  • Creatine protein matrix and method for manufacturing the same
    PatentActiveEP2926669A1
    View detail
  • Oral formulation of creatine derivatives and method of manufacturing same
    PatentInactiveUS20070071815A1
    View detail
  • Process for the preparation of creatine phosphate
    PatentInactiveUS3639211A
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png